Turkey: Amendments Regarding Compulsory Licenses In Turkey

Last Updated: 11 December 2014
Article by Duygu Aksit

Article 31(f) of the TRIPS Agreement1 states that compulsory licenses shall be authorized 'predominantly for the supply of the domestic market' of the Member State authorizing the use of such license. In other words, the importing country cannot grant compulsory licenses with a view to supplying a third country market. In the meantime, developing countries have long argued that the above-stated article is hampering access to medicines as only very few developing countries have a significant manufacturing capacity2. This was first mentioned in Paragraph 6 of the Doha Declaration3 as follows:

"We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement."

Subsequently, I mplementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health 4 (hereby the Decision 2003) was introduced in August 2003 in order to provide for Member States to waive from the obligation set out in Article 31(f); allowing for the first importing country to manufacture, export and import pharmaceutical products to third countries in need 5 .

The Decision 2003 was followed by the Decision 2005 6 incorporating Article 31bis to the TRIPS Agreement aiming at making the waiver permanent 7 . The amendment will not be in force until two thirds of WTO Members formally accept it. The amendment will be open for acceptance until '31 December 2015 or such later date as may be decided by the Ministerial Conference 8 '. This deadline may well be extended once more as several deadlines have been adopted in the past in an effort to constrain WTO Members to expedite acceptance 9 . However, a majority has not been met as of today 10 .

Turkey, alongside with countries such as Israel, Mexico, Singapore, United Arab Emirates, has declared that the system will only be used in case of national emergencies or other circumstances of extreme urgency11.

Turkey expressed its intention to join the club on the account of the fact that "... it is quite probable that our country [Turkey], with a significant manufacturing capacity, will make use of the Paragraph 6 system as an exporter country12." The joint approval of the Council of Ministers and the President was published on the Official Gazette which corresponds to an official acceptance of the Decision 2005. Subsequently, the instrument of acceptance has been duly notified to the World Trade Organization13.

First and foremost, it should be borne in mind that this is not an actual implementation of the mechanism into the domestic law. However, a Draft Law14 amending the current legislation on protection of patent rights15 (hereby the Draft Law) – which has been included in the parliament agenda in 2013 and is awaiting to be evaluated by the MPs – will provide that a new section be added among other grounds for granting compulsory licenses, namely, failure to work the invention, dependency of patents and public interest. The wording of the Draft Law enables 'the exportation of compulsory licenses to third countries facing public health related problems provided that the conditions in the Regulation are met'. The Regulation is not available yet however it appears to be as vital as the underlying Draft Law.

For instance, Turkish Law requires prior negotiations under all circumstances16 – which may be time consuming and thus be considered as an obstacle with regard to making drugs accessible in case of emergencies. Such procedure may also put generic manufacturers into a disadvantageous position in the event that they do not have prior contacts or experience17. Such difficulties raised by formalities may be diminished by a well-functioning Regulation as in Regulation (EC) No 816/2006 of the European Union18, according to which a separate fast track operates in the event of national emergency, other circumstances of extreme urgency and public non-commercial use.

In light of all the foregoing, it is acknowledged in the Decision 2003 that the domestic supply clause is a hindrance to providing cheaper medicines and that a permanent waiver to the TRIPS Agreement would be a means to overcome such problem. Turkey, a "pharmerging" market, took a stand in line with said Decision and will take this intention one step forward once the mechanism will actually be implemented into the domestic law.


1 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Marrakesh, 15 April 1994.

2 Carlos M. Correa, "Trade Related Aspects of Intellectual Property Rights, A Commentary on the TRIPS Agreement", (New York: Oxford University Press, 2007), 303.

3 Declaration on the TRIPS Agreement and Public Health , Doha, 14 November 2001.

4 World Trade Organization, Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health, Decision of the General Council of 30 August 2003.

5 Roy Love, "Corporate Wealth or Public Health? WTO/TRIPS Flexibilities and Access to HIV/AIDS Antiretroviral Drugs by Developing Countries", Development in Practice, Vol. 17, No. 2, April 2007, 208-219.

6 World Trade Organization, Amendment of the TRIPS Agreement, Decision of the General Council of 6 December 2005.

7 World Trade Organization, Press/426, INTELLECTUAL PROPERTY: Members OK amendment to make health flexibility permanent, 6 December 2005. http://www.wto.org/english/news_e/pres05_e/pr426_e.htm Date of Access: 12.05.2014.

8 WT/L/899, World Trade Organization, Amendment of the TRIPS Agreement – Fourth Extension of the Period for the Acceptance by Members of the Protocol Amending the TRIPS Agreement, Decision of 26 November 2013.

9 WT/L/711, World Trade Organization, Amendment of the TRIPS Agreement – Extension of the Period for the Acceptance by Members of the Protocol Amending the TRIPS Agreement,Decision of 18 December 2007.

WT/L/785, World Trade Organization, Amendment of the TRIPS Agreement – Second Extension of the Period for the Acceptance by Members of the Protocol Amending the TRIPS Agreement, Decision of 17 December 2009.

WT/L/829, World Trade Organization, Amendment of the TRIPS Agreement – Third Extension of the Period for the Acceptance by Members of the Protocol Amending the TRIPS Agreement, Decision of 30 November 2011.

10 World Trade Organization, Intellectual Property: Members accepting amendment of the TRIPS Agreement. http://www.wto.org/english/tratop_e/trips_e/amendment_e.htm Date of Access: 11.05.2014

11 See note 7 above.

12 Law No. 6471 of 30.04.2014, OG No: 28654, 23.05.2013.

13 See note 10 above.

14 Draft law amending Decree-Law No. 551 on the Protection of Patent Rights, http://www2.tbmm.gov.tr/d24/1/1-0756.pdf (Only available in Turkish) Date of Access: 12.05.2014

15 Decree-Law No. 551 of 06.24.1995 on the Protection of Patent Rights, OG No: 22326, 27.06.1995. http://www.wipo.int/wipolex/en/text.jsp?file_id=314870 Date of Access: 12.05.2014.

16 Ünal Tekinalp, "Fikri Mülkiyet Hukuku", 5th ed. (Istanbul: Vedat Kitapcilik, 2012), 616-618.

17 Katri Paas, "Compulsory licensing under the TRIPS Agreement – a cruel taunt for developing countries?", E.I.P.R. 2009, 31(12), 609-613.

18 Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems, OJ 2006 L/157/1.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.